Post-earnings recap
Reported
Thu, Jul 28, 2016
EPS actual
$0.83
EPS est.
$0.42
EPS surprise
+96.22%
1-day move
+8.72%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
AstraZeneca's strong EPS performance significantly exceeded expectations, leading to an 8.72% increase in stock price. The company did not provide revenue figures or future guidance, but management's positive tone suggests confidence in ongoing projects and product development. Investors may view this earnings beat as a sign of strong operational execution.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.83 | N/A | +96.22% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the earnings performance, particularly the strong EPS results. They emphasized their commitment to innovation and growth.
We are pleased with our progress this quarter.
Our focus remains on delivering innovative medicines.